Pure Global
NCT06359626

Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers

An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate Bioequivalence Between YHP2205 and YHR2401 in Healthy Subjects
Yuhan Corporation·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteers
Drug/Device/Intervention
YHP2205
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yuhan Corporation
Timeline & enrollment
Phase
Phase 1
Start date
May 27, 2024
End date
Jul 06, 2024
Enrollment
60 participants
Primary outcome

Area under the plasma drug concentration-time curve [AUCt],Maximum plasma concentration [Cmax]

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to
 investigate the bioequivalence between YHP2205 and YHR2401 in healthy volunteers

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06359626
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06359626 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yuhan Corporation and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.